Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.P02 Monotherapy or in Combination With Pembrolizumab in Advanced CLDN1+ Squamous Solid Tumors
NCT06747585Phase 2Recruiting
- Sponsor
- Alentis Therapeutics
- Start
- Dec 2024
- Primary completion
- Feb 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
A Phase 2 trial of ALE.P02 in non-small cell lung cancer, squamous cell carcinoma (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma (CSCC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Alentis Therapeutics. Started Dec 2024; status: recruiting.
02
Drugs
ALE.P02
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)head and neck squamous cell carcinoma (HNSCC)cervical squamous cell carcinoma (CSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06747585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747585.